TW200633692A - Use of alpha-adrenergic blockers for the treatment of dysmenorrhea - Google Patents

Use of alpha-adrenergic blockers for the treatment of dysmenorrhea

Info

Publication number
TW200633692A
TW200633692A TW094143868A TW94143868A TW200633692A TW 200633692 A TW200633692 A TW 200633692A TW 094143868 A TW094143868 A TW 094143868A TW 94143868 A TW94143868 A TW 94143868A TW 200633692 A TW200633692 A TW 200633692A
Authority
TW
Taiwan
Prior art keywords
alpha
dysmenorrhea
adrenergic blockers
treatment
tamsulosin
Prior art date
Application number
TW094143868A
Other languages
English (en)
Inventor
Giora Davidai
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of TW200633692A publication Critical patent/TW200633692A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094143868A 2004-12-13 2005-12-12 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea TW200633692A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63592504P 2004-12-13 2004-12-13
US72650605P 2005-10-13 2005-10-13

Publications (1)

Publication Number Publication Date
TW200633692A true TW200633692A (en) 2006-10-01

Family

ID=36168388

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094143868A TW200633692A (en) 2004-12-13 2005-12-12 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea

Country Status (7)

Country Link
US (1) US20060128719A1 (zh)
EP (1) EP1827404A2 (zh)
JP (1) JP2008523143A (zh)
AR (1) AR051791A1 (zh)
CA (1) CA2588017A1 (zh)
TW (1) TW200633692A (zh)
WO (1) WO2006065555A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939432B2 (ja) 2004-12-01 2012-05-23 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ α−シヌクレイン毒性のモジュレーター
AU2006247351A1 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
US8501465B2 (en) 2007-12-21 2013-08-06 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US20160220515A1 (en) 2013-09-06 2016-08-04 The University Of Montana Method of reducing neuronal cell death with haloalkylamines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
CA2104873C (en) * 1991-02-26 2000-05-23 James N. Campbell Compositions and methods of treatment of sympathetically maintained pain
ATE219933T1 (de) * 1992-09-18 2002-07-15 Yamanouchi Pharma Co Ltd Hydrogelzubereitung mit verzögerter freisetzung
EP0942911B1 (en) * 1996-12-06 2001-10-17 Abbott Laboratories Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
US6376488B1 (en) * 2000-09-07 2002-04-23 Abbott Laboratories Benzoxazine α-1 adrenergic compounds

Also Published As

Publication number Publication date
CA2588017A1 (en) 2006-06-22
US20060128719A1 (en) 2006-06-15
AR051791A1 (es) 2007-02-07
WO2006065555A2 (en) 2006-06-22
EP1827404A2 (en) 2007-09-05
JP2008523143A (ja) 2008-07-03
WO2006065555A3 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
IL259741A (en) A method for treating cancer resistant to gefitinib
TW200633692A (en) Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
TW200603807A (en) Method for the treatment of premenstrual and other female sexual disorders
TW200507849A (en) Methods for treating interleukin-6 related diseases
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
HK1120441A1 (en) Drugs for treatment of ovarian cancer
EA201691939A1 (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
EP1750730A4 (en) TREATMENT OF HYPERCHOLESTERINEMIA, HYPERTRIGLYCERIDEMIA, AND HEART CIRCUIT-RELATED TREATMENTS USING PHOSPHALIPASE A2 INHIBITORS
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
ATE424208T1 (de) Proteinkinaseinhibitoren
PH12016502353A1 (en) Pharmaceutical composition
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
ATE551052T1 (de) Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
MX2022000845A (es) Compuestos inhibidores.
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
IL286983A (en) Methods of treating chronic spontaneous urticaria using Bruton's tyrosine kinase inhibitor
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
TW200806283A (en) Therapeutic methods
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
EA202192961A1 (ru) Ребамипид для применения в профилактике и/или лечении синуклеинопатий